Werkgroep Cardiologische centra Nederland

TECOS (Completed)

A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment With Sitagliptin in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (TECOS)
Medicine
Sitagliptin
Population
ASCVD
Phase
III
Starting year
2008
More information
Clinicaltrials.gov

Director of Study

dr. J.H. Cornel (Cardioloog)
Alkmaar, Noordwest Ziekenhuisgroep

Publications: TECOS

  • Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes: International Insights from the TECOS TrialCirculation - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Safety of Sitagliptin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Outcomes from TECOSDiabetes Obes Metab - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOSDiabetes Care - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.JAMA Cardiol. - Abstract - Cornel, dr. J.H. - TECOS - ASCVD
  • Discussant review: impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Impact of Sitagliptin  on Heart Failure and  Related OutcomesESC 2015 - TECOS - ASCVD
  • Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine - TECOS - ASCVD

Publications by WCN study

Publications WCN studies by WCN member